A two-step strategy for disaccharide modulation using vancomycin as a model is reported. The strategy relies upon a glycosyltransferase-catalyzed 'reverse' reaction to enable the facile attachment of an alkoxyamine-bearing sugar to the vancomycin core. Neoglycosylation of the corresponding aglycon led to a novel set of vancomycin 1,6-disaccharide variants. While the in vitro antibacterial properties of corresponding vancomycin 1,6-disaccharide analogs were equipotent to the parent antibiotic, the chemoenzymatic method presented is expected to be broadly applicable.
herein we describe the synthesis of 2-chloro-4-nitrophenyl 6′-deoxy-6′-methoxyamino-β-Dglucopyranoside and its application as a novel donor for: i) direct NDP-6′-deoxy-6′-methoxyamino-D-glucose synthesis, and ii) in situ two GT-catalyzed attachment of 6′deoxy-6′-methoxyamino-D-glucose to the vancomycin aglycon for subsequent chemoselective neoglycosylation through a selective reaction between free reducing sugar and the alkoxyamine handle. 4 Cumulatively, this model study illustrates a new general platform to generate disaccharide analogs of complex natural products with anticipated broad applicability.
The activated alkoxyaminosugar donor 1 for this study was synthesized in 8 steps with an overall yield of 46% (see supporting information and supplementary figure S1). Donor 1 was subsequently assessed as a substrate for the GT-catalyzed production of 2 in the presence of UDP and the enhanced GT (OleD TDP16) (see supplementary figure S2 ). 5 This reaction was conducted with a 1:1 ratio of glycoside donor to UDP and, after HPLC purification, provided 68 mg (88% isolated yield) of the desired product (2) (see supporting information for full characterization). This illustrated efficiency of the OleD TDP16-catalyzed reverse reaction with the non-native donor 1 sugar sets the stage for a potential one-pot procedure for alkoxyaminosugar attachment to the model vancomycin aglycon as described below and also provides a facile route to a potentially new reagent for glycobiology.
The complex natural product model selected for this study (the glycopeptide vancomycin) is a treatment of last resort for certain antibiotic-resistant Gram-positive pathogens. 6 The selection for this model was based upon the known impact of sugar modification upon improving the activity of vancomycin analogs against vancomycin-resistance bacteria, 4f,7 and the permissive nature of the vancomycin GT GtfE. 8 Vancomycin aglycon (3) was readily obtained by acid hydrolysis of vancomycin. 4f,9 and with the simple activated 2-chloro-4-nitrophenyl glycoside (1) in hand we attempted to form the monoglycosylated vancomycin derivative (4) using a dual-GT-catalyzed coupled reaction ( Figure 1C ). The optimized single-pot reaction (50 mM Tris-HCl buffer, pH 8.5; 1.2 mM donor 1; 1 mM UDP; 1 mM vancomycin aglycon 3; 4 μM OleD TDP16; 10 μM GtfE; 30 °C) was followed by analytical HPLC (see supplementary figure S5 ). Notably, conversion to the desired product (4) in this one pot reaction (47%) was comparable to the GtfE-catalyzed production of 4 directly from UDP-Glc and 3 (53%). 3 To generate sufficient material for downstream neoglycosylation, the dual-GT-catalyzed reaction was scaled (200 mL reaction volume) which, after deproteination and simple purification, afforded 150 mg of the desired product 4 (35% isolated yield, see supplementary material for full characterization) for subsequent neoglycosylation using representative sugars found within the bacterial cell wall or appended to glycopeptides.
A wide variety of uniquely functionalized carbohydrates decorate the peptide backbone of naturally-occurring glycopeptides and other antibiotics. Most of these sugars fall within the hexo-and 6-deoxyhexopyranosides and include D-glucose, L-rhamnose, L-vancosamine, Dglucosamine and the 2′-N-acyl-D-glucolipid found in teicoplanin (6). 10 In addition to these four sugars represented among glycopeptides, we also selected the highly deoxygenated Dforosamine from the macrolide spiramycin (7) and insecticidal spinosyns (8) (Figure 2 ) 11 and N-acetyl-muramic acid, a main component of bacterial peptidoglycan. Among this series, D-glucose, L-rhamnose, D-glucosamine and N-acetyl-muramic acid were commercially available, a representative 2′-N-acyl-D-glucolipid was synthesized as previously described, 4f while D-forosamine and L-vancosamine were generated via acid hydrolysis of spiramycin and alloc-protected vancomycin, respectively. 9 For the pilot reaction, compound 4 was dissolved in DMSO/AcOH, followed by the addition of a 10-fold excess of D-glucose. The reaction was allowed to proceed at 40 °C and monitored by HPLC.
Within 16 h, the starting material was fully consumed, and the newly generated material (9) was subsequently isolated by preparative HPLC. Neoglycosides 10 to 16 were generated in identical fashion (isolated yields from 31 to 95%, see supplementary materials for full characterization) and, with the exception of compound 10 which was formed as an α/β (1:2) mixture, exclusive formation of a single anomer was observed. HMBC and ROESY experiments revealed a strong correlation between the anomeric proton of the neoglycoside with C-6 and H-6 of the alkoxyaminosugar respectively, supporting the regioselectivity of attachment (see supplementary Figure S8 ).
Neoglycosides 9-16 and aglycon 3 were found to inhibit growth of two methicillin-resistant (33491 and MW2) bacteria at a concentration between 0.25 to 16 μg/mL (MIC of vancomycin 5 = 0.5 and 0.25 μg/mL respectively), whereas no significant growth inhibition of vancomycin-resistant strains (Van A 256, VA-21) by 9-16 was observe (MIC = 64 μg/ mL) (see supplemental Table S3 ). Thus, while the current range of analogs were unable to circumvent resistance mechanisms, this analysis suggests that 1,6-neoglycosyl modification does not infringe upon the standard vancomycin mechanism of action. More importantly, this model study illustrates an enabling platform for the disaccharide modification of complex biomolecules for which permissive glycosyltransferases are available. 12 
Supplementary Material
Refer to Web version on PubMed Central for supplementary material. (A) Classical GT reaction in which glycoside formation is thermodynamically favored. (B) GT reaction where an appropriately 'activated' glycoside donor (Donor*) shifts the reaction thermodynamics to favor sugar nucleotide formation. (C) One-pot coupled dual-GTcatalyzed reaction which combines GT-driven (OleD) sugar nucleotide synthesis with a subsequent GT-catalyzed (GtfE) glycosylation reaction to ultimately accomplish transglycosylation from a synthetic aromatic glycoside to a targeted aglycon (in this case, the vancomycin aglycon 3). Structures of the natural glycopeptide antibiotics vancomycin (5) and teicoplanin (6) and known natural products containing D-forosamine. The neoglycosylation of the 6′-alkoxyaminosugar-substituted vancomycin neoaglycon (4) (upper). The products of the neoglycosylation reaction with corresponding conversions based upon HPLC are illustrated (lower). Full characterization of 9-16 is presented in supporting information.
